• Birinapant is a second generation bivalent SMAC mimetic in development for cancer and Hepatitis B.
  • SHAPE SHAPE is a novel HDAC inhibitor being developed for topical use in early-stage CTCL.

Active Clinical Programs

OncologyPhase 1Phase 2Phase 3
Cutaneous T-Cell Lymphoma (CTCL)SHAPE
Infectious Disease
Hepatitis BBirinapant